326 related articles for article (PubMed ID: 18579431)
1. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
4. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
Lövborg H; Oberg F; Rickardson L; Gullbo J; Nygren P; Larsson R
Int J Cancer; 2006 Mar; 118(6):1577-80. PubMed ID: 16206267
[TBL] [Abstract][Full Text] [Related]
6. [Proteasome inhibitors--new option in the treatment of tumor diseases].
Spicka I; Klener P
Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition as novel treatment strategy in leukaemia.
Vink J; Cloos J; Kaspers GJ
Br J Haematol; 2006 Aug; 134(3):253-62. PubMed ID: 16787504
[TBL] [Abstract][Full Text] [Related]
8. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
9. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
12. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Chen D; Cui QC; Yang H; Dou QP
Cancer Res; 2006 Nov; 66(21):10425-33. PubMed ID: 17079463
[TBL] [Abstract][Full Text] [Related]
13. An historic perspective of proteasome inhibition.
Esseltine DL; Mulligan G
Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of proteasome inhibitor action and resistance in cancer.
McConkey DJ; Zhu K
Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
[TBL] [Abstract][Full Text] [Related]
16. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Milacic V; Chen D; Ronconi L; Landis-Piwowar KR; Fregona D; Dou QP
Cancer Res; 2006 Nov; 66(21):10478-86. PubMed ID: 17079469
[TBL] [Abstract][Full Text] [Related]
17. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition: a new therapeutic strategy to cancer treatment.
Wu WK; Cho CH; Lee CW; Wu K; Fan D; Yu J; Sung JJ
Cancer Lett; 2010 Jul; 293(1):15-22. PubMed ID: 20133049
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
20. Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
Abayomi EA; Sissolak G; Jacobs P
Transfus Apher Sci; 2007 Aug; 37(1):85-92. PubMed ID: 17881293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
